USA - engelsk - NLM (National Library of Medicine)

wockhardt usa llc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

USA - engelsk - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in using enalapril maleate tablets usp consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets usp does not have a similar risk (see warnings, neutropenia/agranulocytosis). in considering use of enalapril maleate tablets usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. do not coadminister aliskiren with enalapril maleate in patients with diabetes (see precautions, drug interactions ). enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings, head and neck angioedema ).

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hexal ag industriestrasse 25 d-83607 holzkirchen (duitsland) - enalaprilmaleaat 30 mg/stuk samenstelling overeenkomend met ; enalapril 22,9 mg/stuk - tablet - ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumwaterstofcarbonaat (e 500 (ii)) ; talk (e 553 b), - enalapril

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hexal ag - enalaprilmaleaat samenstelling overeenkomend met ; enalapril - tablet - ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumwaterstofcarbonaat (e 500 (ii)) ; talk (e 553 b), - enalapril

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hexal ag industriestrasse 25 d-83607 holzkirchen (duitsland) - enalaprilmaleaat 40 mg/stuk samenstelling overeenkomend met ; enalapril 30,6 mg/stuk - tablet - ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumwaterstofcarbonaat (e 500 (ii)) ; talk (e 553 b), - enalapril

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

hexal ag - enalaprilmaleaat samenstelling overeenkomend met ; enalapril - tablet - ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumwaterstofcarbonaat (e 500 (ii)) ; talk (e 553 b), - enalapril

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 20 mg; hydrochlorothiazide, quantity: 6 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium bicarbonate; maize starch; lactose monohydrate; purified talc - mild to moderate hypertension. treatment should not be initiated with this fixed dose combination.

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - enalapril - comprimido - 5 mg - enalapril, maleato 5 mg - enalapril - genérico - duração do tratamento: longa duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - enalapril - comprimido - 20 mg - enalapril, maleato 20 mg - enalapril - genérico - duração do tratamento: longa duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - enalapril - comprimido - 5 mg - enalapril, maleato 5 mg - enalapril - genérico - duração do tratamento: longa duração